Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Black Lung Disease Market

ID: MRFR/Pharma/4256-HCR
200 Pages
Vikita Thakur
Last Updated: May 15, 2026

Black Lung Disease Market Research Report By Disease Type (Chronic Obstructive Pulmonary Disease, Pneumoconiosis, Coal Workers' Pneumoconiosis), By Diagnostic Method (Chest X-ray, CT Scan, Pulmonary Function Test), By Treatment Type (Medication, Pulmonary Rehabilitation, Surgical Procedures), By End User (Hospitals, Diagnostic Laboratories, Research Institutes) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY Disease Type (USD Billion) | |
      1. 4.1.1 Chronic Obstructive Pulmonary Disease | |
      2. 4.1.2 Pneumoconiosis | |
      3. 4.1.3 Coal Workers' Pneumoconiosis |
    2. 4.2 Healthcare, BY Diagnostic Method (USD Billion) | |
      1. 4.2.1 Chest X-Ray | |
      2. 4.2.2 CT Scan | |
      3. 4.2.3 Pulmonary Function Test |
    3. 4.3 Healthcare, BY Treatment Type (USD Billion) | |
      1. 4.3.1 Medication | |
      2. 4.3.2 Pulmonary Rehabilitation | |
      3. 4.3.3 Surgical Procedures |
    4. 4.4 Healthcare, BY End User (USD Billion) | |
      1. 4.4.1 Hospitals | |
      2. 4.4.2 Diagnostic Laboratories | |
      3. 4.4.3 Research Institutes |
    5. 4.5 Healthcare, BY Region (USD Billion) | |
      1. 4.5.1 North America | | |
        1. 4.5.1.1 US | | |
        2. 4.5.1.2 Canada | |
      2. 4.5.2 Europe | | |
        1. 4.5.2.1 Germany | | |
        2. 4.5.2.2 UK | | |
        3. 4.5.2.3 France | | |
        4. 4.5.2.4 Russia | | |
        5. 4.5.2.5 Italy | | |
        6. 4.5.2.6 Spain | | |
        7. 4.5.2.7 Rest of Europe | |
      3. 4.5.3 APAC | | |
        1. 4.5.3.1 China | | |
        2. 4.5.3.2 India | | |
        3. 4.5.3.3 Japan | | |
        4. 4.5.3.4 South Korea | | |
        5. 4.5.3.5 Malaysia | | |
        6. 4.5.3.6 Thailand | | |
        7. 4.5.3.7 Indonesia | | |
        8. 4.5.3.8 Rest of APAC | |
      4. 4.5.4 South America | | |
        1. 4.5.4.1 Brazil | | |
        2. 4.5.4.2 Mexico | | |
        3. 4.5.4.3 Argentina | | |
        4. 4.5.4.4 Rest of South America | |
      5. 4.5.5 MEA | | |
        1. 4.5.5.1 GCC Countries | | |
        2. 4.5.5.2 South Africa | | |
        3. 4.5.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 United States Department of Labor (US) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 National Institute for Occupational Safety and Health (US) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Coalition for Occupational Safety and Health (US) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 American Lung Association (US) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 National Black Lung Association (US) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Mine Safety and Health Administration (US) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 American College of Chest Physicians (US) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 American Thoracic Society (US) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY DISEASE TYPE |
    7. 6.4 US MARKET ANALYSIS BY DIAGNOSTIC METHOD |
    8. 6.5 US MARKET ANALYSIS BY TREATMENT TYPE |
    9. 6.6 US MARKET ANALYSIS BY END USER |
    10. 6.7 CANADA MARKET ANALYSIS BY DISEASE TYPE |
    11. 6.8 CANADA MARKET ANALYSIS BY DIAGNOSTIC METHOD |
    12. 6.9 CANADA MARKET ANALYSIS BY TREATMENT TYPE |
    13. 6.10 CANADA MARKET ANALYSIS BY END USER |
    14. 6.11 EUROPE MARKET ANALYSIS |
    15. 6.12 GERMANY MARKET ANALYSIS BY DISEASE TYPE |
    16. 6.13 GERMANY MARKET ANALYSIS BY DIAGNOSTIC METHOD |
    17. 6.14 GERMANY MARKET ANALYSIS BY TREATMENT TYPE |
    18. 6.15 GERMANY MARKET ANALYSIS BY END USER |
    19. 6.16 UK MARKET ANALYSIS BY DISEASE TYPE |
    20. 6.17 UK MARKET ANALYSIS BY DIAGNOSTIC METHOD |
    21. 6.18 UK MARKET ANALYSIS BY TREATMENT TYPE |
    22. 6.19 UK MARKET ANALYSIS BY END USER |
    23. 6.20 FRANCE MARKET ANALYSIS BY DISEASE TYPE |
    24. 6.21 FRANCE MARKET ANALYSIS BY DIAGNOSTIC METHOD |
    25. 6.22 FRANCE MARKET ANALYSIS BY TREATMENT TYPE |
    26. 6.23 FRANCE MARKET ANALYSIS BY END USER |
    27. 6.24 RUSSIA MARKET ANALYSIS BY DISEASE TYPE |
    28. 6.25 RUSSIA MARKET ANALYSIS BY DIAGNOSTIC METHOD |
    29. 6.26 RUSSIA MARKET ANALYSIS BY TREATMENT TYPE |
    30. 6.27 RUSSIA MARKET ANALYSIS BY END USER |
    31. 6.28 ITALY MARKET ANALYSIS BY DISEASE TYPE |
    32. 6.29 ITALY MARKET ANALYSIS BY DIAGNOSTIC METHOD |
    33. 6.30 ITALY MARKET ANALYSIS BY TREATMENT TYPE |
    34. 6.31 ITALY MARKET ANALYSIS BY END USER |
    35. 6.32 SPAIN MARKET ANALYSIS BY DISEASE TYPE |
    36. 6.33 SPAIN MARKET ANALYSIS BY DIAGNOSTIC METHOD |
    37. 6.34 SPAIN MARKET ANALYSIS BY TREATMENT TYPE |
    38. 6.35 SPAIN MARKET ANALYSIS BY END USER |
    39. 6.36 REST OF EUROPE MARKET ANALYSIS BY DISEASE TYPE |
    40. 6.37 REST OF EUROPE MARKET ANALYSIS BY DIAGNOSTIC METHOD |
    41. 6.38 REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE |
    42. 6.39 REST OF EUROPE MARKET ANALYSIS BY END USER |
    43. 6.40 APAC MARKET ANALYSIS |
    44. 6.41 CHINA MARKET ANALYSIS BY DISEASE TYPE |
    45. 6.42 CHINA MARKET ANALYSIS BY DIAGNOSTIC METHOD |
    46. 6.43 CHINA MARKET ANALYSIS BY TREATMENT TYPE |
    47. 6.44 CHINA MARKET ANALYSIS BY END USER |
    48. 6.45 INDIA MARKET ANALYSIS BY DISEASE TYPE |
    49. 6.46 INDIA MARKET ANALYSIS BY DIAGNOSTIC METHOD |
    50. 6.47 INDIA MARKET ANALYSIS BY TREATMENT TYPE |
    51. 6.48 INDIA MARKET ANALYSIS BY END USER |
    52. 6.49 JAPAN MARKET ANALYSIS BY DISEASE TYPE |
    53. 6.50 JAPAN MARKET ANALYSIS BY DIAGNOSTIC METHOD |
    54. 6.51 JAPAN MARKET ANALYSIS BY TREATMENT TYPE |
    55. 6.52 JAPAN MARKET ANALYSIS BY END USER |
    56. 6.53 SOUTH KOREA MARKET ANALYSIS BY DISEASE TYPE |
    57. 6.54 SOUTH KOREA MARKET ANALYSIS BY DIAGNOSTIC METHOD |
    58. 6.55 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE |
    59. 6.56 SOUTH KOREA MARKET ANALYSIS BY END USER |
    60. 6.57 MALAYSIA MARKET ANALYSIS BY DISEASE TYPE |
    61. 6.58 MALAYSIA MARKET ANALYSIS BY DIAGNOSTIC METHOD |
    62. 6.59 MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE |
    63. 6.60 MALAYSIA MARKET ANALYSIS BY END USER |
    64. 6.61 THAILAND MARKET ANALYSIS BY DISEASE TYPE |
    65. 6.62 THAILAND MARKET ANALYSIS BY DIAGNOSTIC METHOD |
    66. 6.63 THAILAND MARKET ANALYSIS BY TREATMENT TYPE |
    67. 6.64 THAILAND MARKET ANALYSIS BY END USER |
    68. 6.65 INDONESIA MARKET ANALYSIS BY DISEASE TYPE |
    69. 6.66 INDONESIA MARKET ANALYSIS BY DIAGNOSTIC METHOD |
    70. 6.67 INDONESIA MARKET ANALYSIS BY TREATMENT TYPE |
    71. 6.68 INDONESIA MARKET ANALYSIS BY END USER |
    72. 6.69 REST OF APAC MARKET ANALYSIS BY DISEASE TYPE |
    73. 6.70 REST OF APAC MARKET ANALYSIS BY DIAGNOSTIC METHOD |
    74. 6.71 REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE |
    75. 6.72 REST OF APAC MARKET ANALYSIS BY END USER |
    76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
    77. 6.74 BRAZIL MARKET ANALYSIS BY DISEASE TYPE |
    78. 6.75 BRAZIL MARKET ANALYSIS BY DIAGNOSTIC METHOD |
    79. 6.76 BRAZIL MARKET ANALYSIS BY TREATMENT TYPE |
    80. 6.77 BRAZIL MARKET ANALYSIS BY END USER |
    81. 6.78 MEXICO MARKET ANALYSIS BY DISEASE TYPE |
    82. 6.79 MEXICO MARKET ANALYSIS BY DIAGNOSTIC METHOD |
    83. 6.80 MEXICO MARKET ANALYSIS BY TREATMENT TYPE |
    84. 6.81 MEXICO MARKET ANALYSIS BY END USER |
    85. 6.82 ARGENTINA MARKET ANALYSIS BY DISEASE TYPE |
    86. 6.83 ARGENTINA MARKET ANALYSIS BY DIAGNOSTIC METHOD |
    87. 6.84 ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE |
    88. 6.85 ARGENTINA MARKET ANALYSIS BY END USER |
    89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE TYPE |
    90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSTIC METHOD |
    91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE |
    92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER |
    93. 6.90 MEA MARKET ANALYSIS |
    94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY DISEASE TYPE |
    95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY DIAGNOSTIC METHOD |
    96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE |
    97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY END USER |
    98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY DISEASE TYPE |
    99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY DIAGNOSTIC METHOD |
    100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE |
    101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY END USER |
    102. 6.99 REST OF MEA MARKET ANALYSIS BY DISEASE TYPE |
    103. 6.100 REST OF MEA MARKET ANALYSIS BY DIAGNOSTIC METHOD |
    104. 6.101 REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE |
    105. 6.102 REST OF MEA MARKET ANALYSIS BY END USER |
    106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
    107. 6.104 RESEARCH PROCESS OF MRFR |
    108. 6.105 DRO ANALYSIS OF HEALTHCARE |
    109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
    112. 6.109 HEALTHCARE, BY DISEASE TYPE, 2024 (% SHARE) |
    113. 6.110 HEALTHCARE, BY DISEASE TYPE, 2024 TO 2035 (USD Billion) |
    114. 6.111 HEALTHCARE, BY DIAGNOSTIC METHOD, 2024 (% SHARE) |
    115. 6.112 HEALTHCARE, BY DIAGNOSTIC METHOD, 2024 TO 2035 (USD Billion) |
    116. 6.113 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE) |
    117. 6.114 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion) |
    118. 6.115 HEALTHCARE, BY END USER, 2024 (% SHARE) |
    119. 6.116 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion) |
    120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    121. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
      3. 7.2.3 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      4. 7.2.4 BY END USER, 2025-2035 (USD Billion) |
    123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.3.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
      3. 7.3.3 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      4. 7.3.4 BY END USER, 2025-2035 (USD Billion) |
    124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.4.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
      3. 7.4.3 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      4. 7.4.4 BY END USER, 2025-2035 (USD Billion) |
    125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.5.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
      3. 7.5.3 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      4. 7.5.4 BY END USER, 2025-2035 (USD Billion) |
    126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.6.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
      3. 7.6.3 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      4. 7.6.4 BY END USER, 2025-2035 (USD Billion) |
    127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.7.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
      3. 7.7.3 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      4. 7.7.4 BY END USER, 2025-2035 (USD Billion) |
    128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.8.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
      3. 7.8.3 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      4. 7.8.4 BY END USER, 2025-2035 (USD Billion) |
    129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.9.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
      3. 7.9.3 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      4. 7.9.4 BY END USER, 2025-2035 (USD Billion) |
    130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.10.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
      3. 7.10.3 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      4. 7.10.4 BY END USER, 2025-2035 (USD Billion) |
    131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.11.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
      3. 7.11.3 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      4. 7.11.4 BY END USER, 2025-2035 (USD Billion) |
    132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.12.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
      3. 7.12.3 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      4. 7.12.4 BY END USER, 2025-2035 (USD Billion) |
    133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.13.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
      3. 7.13.3 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      4. 7.13.4 BY END USER, 2025-2035 (USD Billion) |
    134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.14.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
      3. 7.14.3 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      4. 7.14.4 BY END USER, 2025-2035 (USD Billion) |
    135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.15.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
      3. 7.15.3 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      4. 7.15.4 BY END USER, 2025-2035 (USD Billion) |
    136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.16.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
      3. 7.16.3 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      4. 7.16.4 BY END USER, 2025-2035 (USD Billion) |
    137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.17.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
      3. 7.17.3 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      4. 7.17.4 BY END USER, 2025-2035 (USD Billion) |
    138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.18.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
      3. 7.18.3 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      4. 7.18.4 BY END USER, 2025-2035 (USD Billion) |
    139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.19.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
      3. 7.19.3 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      4. 7.19.4 BY END USER, 2025-2035 (USD Billion) |
    140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.20.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
      3. 7.20.3 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      4. 7.20.4 BY END USER, 2025-2035 (USD Billion) |
    141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.21.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
      3. 7.21.3 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      4. 7.21.4 BY END USER, 2025-2035 (USD Billion) |
    142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.22.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
      3. 7.22.3 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      4. 7.22.4 BY END USER, 2025-2035 (USD Billion) |
    143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.23.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
      3. 7.23.3 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      4. 7.23.4 BY END USER, 2025-2035 (USD Billion) |
    144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.24.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
      3. 7.24.3 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      4. 7.24.4 BY END USER, 2025-2035 (USD Billion) |
    145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.25.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
      3. 7.25.3 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      4. 7.25.4 BY END USER, 2025-2035 (USD Billion) |
    146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.26.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
      3. 7.26.3 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      4. 7.26.4 BY END USER, 2025-2035 (USD Billion) |
    147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.27.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
      3. 7.27.3 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      4. 7.27.4 BY END USER, 2025-2035 (USD Billion) |
    148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.28.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
      3. 7.28.3 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      4. 7.28.4 BY END USER, 2025-2035 (USD Billion) |
    149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.29.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
      3. 7.29.3 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      4. 7.29.4 BY END USER, 2025-2035 (USD Billion) |
    150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
      2. 7.30.2 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) | |
      3. 7.30.3 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      4. 7.30.4 BY END USER, 2025-2035 (USD Billion) |
    151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    152. 7.32 ACQUISITION/PARTNERSHIP | |

Healthcare Market Segmentation

Healthcare By Disease Type (USD Billion, 2025-2035)

  • Chronic Obstructive Pulmonary Disease
  • Pneumoconiosis
  • Coal Workers' Pneumoconiosis

Healthcare By Diagnostic Method (USD Billion, 2025-2035)

  • Chest X-Ray
  • CT Scan
  • Pulmonary Function Test

Healthcare By Treatment Type (USD Billion, 2025-2035)

  • Medication
  • Pulmonary Rehabilitation
  • Surgical Procedures

Healthcare By End User (USD Billion, 2025-2035)

  • Hospitals
  • Diagnostic Laboratories
  • Research Institutes

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions